National Fibromyalgia Association awards Wellbox® with Seal of Approval

Therapeutic Massager eases FM pain while reducing cellulite, studies show

Orange, CA - June 23, 2006

The National Fibromyalgia Association (NFA) recently awarded Wellbox®: The Body Optimizer with the NFA Seal of Approval, making the therapeutic massager only the second product to receive this distinction.

Wellbox® initially made its debut in the health and beauty markets for its revolutionary new treatment of whole-body beatification and wellness. The Wellbox was cleared by the US Food and Drug Administration (FDA) to treat cellulite and its technology to ease muscular pain relief.

But a physician who was using the Wellbox® to reduce her cellulite discovered that the technique also eased her fibromyalgia symptoms of muscle soreness and pain. These findings led the European-based company Guitay, the makers of Wellbox®, to fund further studies, including one by renowned fibromyalgia researcher Dr. I. Jon Russell of the University of Texas Health Science Center at San Antonio . Russell is in the final stages of a clinical trial looking at the Wellbox effect on fibromyalgia.

"It's a rare organization that will dedicate time, effort, and funding to develop clinical trials for an alternative therapy such as Wellbox®," said Lynne Matallana, president of the National Fibromyalgia Association. "Thus, after reviewing all the materials and results of the studies, and ensuring that Wellbox passes our strict guidelines for corporate partnerships, the National Fibromyalgia Association is pleased to award a Seal of Approval to Wellbox®, which has demonstrated its effectiveness in treating the symptoms of fibromyalgia."

"We are very honored to receive the NFA's Seal of Approval for the Wellbox®," said Michel Van Welden of Guitay. "With this partnership, Guitay will further show its commitment to support the services of the NFA while providing a product that is scientifically proven to be safe and beneficial in the management of muscular pain in people suffering from fibromyalgia."

Over 10 million Americans suffer from the long-term pain associated with fibromyalgia. To date, there is no drug approved by the FDA to treat fibromyalgia. Last year, the NFA awarded its first Seal of Approval to 024 Fibromyalgia™, developed by Swiss Medica, Inc.

About the NFA

The National Fibromyalgia Association is a non-profit 501(c)(3) organization whose mission is to develop and execute programs dedicated to improving the quality of life for people with fibromyalgia by increasing the awareness of the public, media, government and medical communities.

For more information, visit the NFA's website at www.FMaware.org or call 714-921-0150.